Rhomboid Intercostal Sub Serratus Plane Block Versus Serratus Anterior Plane Block in Thoractomy
Launched by YASSER S MOSTAFA, MD · Feb 28, 2025
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying two different methods of providing pain relief for patients undergoing thoracotomy, which is a surgical procedure to access the chest cavity. The researchers want to see which technique—Rhomboid intercostal and sub serratus plane block (RISS) or Serratus anterior plane block (SAPB)—is more effective at managing pain after the surgery. Both methods use ultrasound to guide the injection of medication that helps numb the area around the surgery site.
To be eligible for this trial, participants need to be between 18 and 70 years old and scheduled for a unilateral thoracotomy, meaning surgery on one side of the chest. They should also be in good overall health according to specific medical guidelines. People with certain health issues, such as severe heart problems or psychiatric conditions, as well as those who are very overweight or have had recent infections, cannot participate. If you join the trial, you can expect to receive either of the two pain relief methods, and the trial aims to ensure that your pain is managed effectively during your recovery.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients aged 18-70 years.
- • Patients scheduled for unilateral Thoracotomy.
- • American Society of Anesthesiologists (ASA) physical status I-III.
- • Patients who are candidates for general anesthesia.
- • No history of severe allergies to local anesthetics or other medications used during the procedure.
- Exclusion Criteria:
- • ASA PS class ≥ IV patients.
- • obese (BMI ≥ 35) patients.
- • Patients with uncontrolled cardiovascular.
- • patients with neurological deficits, cardiopulmonary, hepatorenal , or metabolic diseases; anticoagulants; any drug allergies.
- • Patients with emergency surgeries or re-do surgeries.
- • Systemic infections or infections at the site of injection.
- • Psychiatric illnesses (schizophrenia, bipolar, uncontrolled anxiety or depression).
- • Narcotic dependency.
About Yasser S Mostafa, Md
Dr. Yasser S. Mostafa, MD, is a distinguished clinical trial sponsor with a strong commitment to advancing medical research and improving patient outcomes. With extensive expertise in clinical methodologies and a focus on innovative therapeutic approaches, Dr. Mostafa leads and supports a range of clinical trials aimed at evaluating new treatments and interventions. His dedication to rigorous scientific standards and ethical practices ensures that all research conducted under his guidance is of the highest quality. Dr. Mostafa's collaborative approach fosters partnerships with healthcare professionals, institutions, and regulatory bodies, further enhancing the impact of his work in the medical community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Madīnat Al Fayyūm, Faiyum Governorate, Egypt
Patients applied
Trial Officials
Mahdy A Abdelhady, MD
Study Chair
Fayoum University
Mohamed A Hamed, MD
Principal Investigator
Fayoum University
Mina M Sobhy, MD
Study Director
Fayoum University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported